IP Library Granted Patent US 12,503,690
Granted Patent B1
US 12,503,690 · App. 19/310,812 · Granted Dec 23, 2025

Reverse transcriptase variants

Inventors: Julie Walker (Wheat Ridge, CO); Bjarne Faurholm (Cape Town, ZA); Ross Wadsworth (Cape Town, ZA); Brian A. Kudlow (Boulder, CO)
Assignee: Watchmaker Genomics, Inc.
C12N9/1276C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,503,690
App. No.
19/310,812
Granted
Dec 23, 2025
Kind
B1
Abstract

The present invention provides MML V reverse transcriptase enzymes with increased thermal stability as compared with wild type MML V and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.

Claims (23)

1 . A reverse transcriptase comprising a polypeptide comprising a sequence of amino acids having at least about 95% sequence identity with the reverse transcriptase of SEQ ID NO: 2, and at least one amino acid substitution selected from:

S at position 89 substituted with G, A, V, L, or I;

G at position 171 substituted with S, C, T, or M;

S at position 265 substituted with C, T, or M;

L at position 267 substituted with D, E, N, or Q;

G at position 323 substituted with H, K, or R;

Y at position 377 substituted with F or M;

T at position 453 substituted with G, A, V, L, or I;

G at position 457 substituted with D, E, N, or Q;

V at position 477 substituted with G, A, L, or I; and

D at position 648 substituted with E, N, or Q.

2 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase comprises the sequence of SEQ ID NO: 4.

3 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase comprises the sequence of SEQ ID NO: 8.

4 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase comprises the sequence of SEQ ID NO: 14.

5 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase exhibits an increased thermal stability relative to the reverse transcriptase shown in SEQ ID NO: 2, such that the activity of the reverse transcriptase at temperatures of about 50° C. or greater is at least 90% of the reverse transcriptase activity of the reverse transcriptase shown in SEQ ID NO: 2 at 42° C.

6 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase exhibits an increased thermal stability relative to the reverse transcriptase shown in SEQ ID NO: 2, such that the activity of the reverse transcriptase at temperatures of about 65° C. or greater is at least 50% of the reverse transcriptase activity of the reverse transcriptase shown in SEQ ID NO: 2 at 42° C.

7 . The reverse transcriptase of claim 1 , further comprising at least one additional amino acid substitution selected from:

D at position 557 substituted with G, A, V, L, or I;

D at position 616 substituted with E, N, or Q; and

E at position 595 substituted with D, N, or Q.

8 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase has the following substitutions relative to the reverse transcriptase of SEQ ID NO: 2: S89A, L105Q, G171S, T196K, H237R, S265T, L267E, N282E, G323K, T339K, Y377F, T453V, G457D, V477I, D648E, and H675D.

9 . The reverse transcriptase of claim 1 , wherein the activity of the reverse transcriptase is improved compared to the reverse transcriptase shown in SEQ ID NO: 2 in the presence of inhibitors of reverse transcription.

10 . The reverse transcriptase of claim 1 , wherein the reverse transcriptase comprises the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 15.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 72695 FRAME 331. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 5, 2025
From: FAURHOLM, BJARNE; WADSWORTH, ROSS
To: WATCHMAKER GENOMICS PROPRIETARY, LTD.
Reel/Frame 073464/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: FAURHOLM, BJARNE; WADSWORTH, ROSS
To: WATCHMAKER GENOMICS PROPRIETARY, LTD.
Reel/Frame 072695/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: KUDLOW, BRIAN; WALKER, JULIE
To: WATCHMAKER GENOMICS, INC.
Reel/Frame 072695/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: WATCHMAKER GENOMICS PROPRIETARY, LTD.
To: WATCHMAKER GENOMICS, INC.
Reel/Frame 072695/0458 →
Continuity (3)
Continuation 18844810
Continuation 17940797 · Sep 8, 2022
Provisional Application 63317634 · Mar 8, 2022
References Cited (28)
US 6210891B1 · Nyren et al. · 2001 [cited by applicant]
US 6306597B1 · Macevicz · 2001 [cited by applicant]
US 6828100B1 · Ronaghi · 2004 [cited by applicant]
US 6833246B2 · Balasubramanian · 2004 [cited by applicant]
US 6911345B2 · Quake et al. · 2005 [cited by applicant]
US 7232656B2 · Balasubramanian et al. · 2007 [cited by applicant]
US 7598035B2 · Macevicz · 2009 [cited by applicant]
US 7835871B2 · Kain et al. · 2010 [cited by applicant]
US 7960120B2 · Rigatti et al. · 2011 [cited by applicant]
US 8209130B1 · Kennedy et al. · 2012 [cited by applicant]
US 8835148B2 · Janulaitis et al. · 2014 [cited by applicant]
US 9580698B1 · Xu et al. · 2017 [cited by applicant]
US 9683251B2 · Janulaitis et al. · 2017 [cited by applicant]
US 10287614B2 · Janulaitis et al. · 2019 [cited by applicant]
US 10358670B2 · Janulaitis et al. · 2019 [cited by applicant]
US 11639499B1 · Walker et al. · 2023 [cited by applicant]
US 20020090618A1 · Smith et al. · 2002 [cited by applicant]
US 20060024681A1 · Smith et al. · 2006 [cited by applicant]
US 20060292611A1 · Berka et al. · 2006 [cited by applicant]
US 20070114362A1 · Feng et al. · 2007 [cited by applicant]
US 20080227661A1 · Hogrefe et al. · 2008 [cited by applicant]
US 20110009278A1 · Kain et al. · 2011 [cited by applicant]
US 20250197821A1 · Walker et al. · 2025 [cited by applicant]
Invitation to Pay Additional Fees for Application No. PCT/US2023/063817, mailed Jun. 6, 2023. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/063817, mailed Aug. 4, 2023. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2023/063817, mailed Sep. 19, 2024. [cited by applicant]
Baba et al., Further increase in thermostability of Moloney murine leukemia virus reverse transcriptase by mutational combination. Protein Eng Des Sel. Aug. 1, 2017;30(8):551-557. doi: 10.1093/protein/gzx046. [cited by applicant]
Karlsson, Counting Molecules in cell-free DNA and single cells RNA. Karolinska Institute of Stockholm, Sweden. 2016. 52 pages. [cited by applicant]